Doxorubicin-based combination chemotherapy for desmoid tumors

Regimen	Number of patients	Duration of therapy (cycles)	Response	Duration of response	Author; year
DOXO plus DTIC	11*	2 to 10 (median 5)	2 CR 4 PR 1 MR 2 SD	29 to 235 months	Patel S; 1993
DOXO plus DTIC	5	4 to 6 (median 5) preoperatively	2 pCR 3 PR	21 to 72 months^¶	Goepfert H; 1982
DOXO plus DTIC plus meloxicam	7	4 to 5 (median 5)	3 CR 4 PR	32.5 to 107.5 (median 74)	Gega M; 2006
DOXO plus DTIC (7 cycles) followed by CARBO plus DTIC	5	6 to 19	1 CR 3 PR 1 SD^Δ	10 to 30 months	Schnitzler M; 1997
DOXO plus Cy, or IF plus VP-16, or IF plus VP-16 plus MITO plus DOXO plus CIS	7	2 to 8 (median 6)	3 OR^◊	3 to 180 months	Okuno S; 2003

DOXO: doxorubicin; DTIC: dacarbazine; CR: complete response; PR: partial response; MR: minor response; SD: stable disease; pCR: pathologic complete response; CARBO: carboplatin; Cy: cyclophosphamide; IF: ifosfamide; VP-16: etoposide; MITO: mitomycin; CIS: cisplatin; OR: objective response; NED: no evidence of disease.
* 9 out of 11 patients were evaluable; 2 patients were treated in the 1970s and could not be evaluated objectively but were reported to have responses that enabled the resection of axillary and pelvic disease.
¶ All patients received chemotherapy preoperatively, only 1 patient recurred after surgery at 21 months. All others remained NED.
Δ Patient progressed rapidly after cessation of chemotherapy.
◊ All patients on chemotherapy showed some form of clinical benefit, such as OR or SD, or symptomatic improvement.

Graphic 71589 Version 3.0